Influence of CYP2C19 genetic variants and smoking on dual antiplatelet efficacy in patients with coronary artery disease
IntroductionThis study aimed to investigate the effects of smoking and CYP2C19 gene polymorphism on antiplatelet therapy to specify the most optimized and accurate antiplatelet therapy for different populations.MethodsThis study included 6,353 patients with coronary artery disease (CAD). In total, 2...
Main Authors: | Yujing Cheng, Yan Sun, Dai Zhang, Xiaoteng Ma, Chi Liu, Chengping Hu, Tienan Sun, Ziwei Zhao, Xiaoli Liu, Yujie Zhou |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-01-01
|
Series: | Frontiers in Cardiovascular Medicine |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fcvm.2023.1105001/full |
Similar Items
-
Impact of CYP2C19 variants on clinical efficacy of clopidogrel and one-year clinical outcomes in coronary heart patients undergoing percutaneous coronary intervention
by: Hong Sun, et al.
Published: (2016-11-01) -
Dual antiplatelet therapy for reduction in mortality in patients with acute and chronic coronary syndromes
by: Maciej Lesiak, et al.
Published: (2021-12-01) -
Real-world experience of clinical management with antiplatelet and lipid-lowering therapy in post acute coronary syndrome patients in Indian setting
by: M S Hiremath, et al.
Published: (2021-01-01) -
Choice of dual antiplatelet therapy in patients with acute coronary syndrome after percutaneous coronary intervention
by: A. N. Golosova, et al.
Published: (2020-08-01) -
ACC/AHA CLOPIDOGREL CLINICAL ALERT. WHAT MUST BE MODERN ANTIPLATELET THERAPY?
by: S. J. Martsevich
Published: (2016-01-01)